PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the […]
PRESS RELEASE: IVI Unveils New Value Assessment Model for Non-Small Cell Lung Cancer
IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R […]
PRESS RELEASE: IVI Launches New Research Brief Series “Value Blueprints”
IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.
PRESS RELEASE: IVI Releases Public Comments on Non-Small Cell Lung Cancer Value Tool
Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model – our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI’s mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to […]
PRESS RELEASE: IVI Illustrates “Insurance Value” Using IVI-RA Model in Latest Research Brief
In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions […]
PRESS RELEASE: How Structural Uncertainty Impacts Value Estimates
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it […]
PRESS RELEASE: IVI Receives Eugene Washington PCORI Engagement Award
IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established and emerging approaches for improving value assessment and then identify and prioritize potential areas for research investment and collaborative solutions. […]
PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors
As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate […]
PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates
IVI has just released the latest update to the organization’s Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to […]
PRESS RELEASE: IVI Announces Six New Members to Board of Directors
IVI is pleased to announce the latest additions to our diverse and growing Board of Directors. Read the full press release here to learn who is helping us drive value assessment to the next level in 2020.